A. Roy

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Hung-Ming Wang, R. Greil, K. Harrington, 2019, The Lancet.

Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

T. Choueiri, D. McDermott, R. Perini, 2021, Journal of Clinical Oncology.

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.

R. Figlin, T. Choueiri, M. Michaelson, 2023, The Lancet. Oncology.

1447O Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003

R. Figlin, R. Perini, A. Roy, 2022, Annals of Oncology.

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

W. Linehan, R. Srinivasan, W. Rathmell, 2021 .

656MO Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)

T. Choueiri, D. McDermott, R. Perini, 2021, Annals of Oncology.

Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.

L. Appleman, A. Roy, T. Bauer, 2023, European journal of cancer.